Pasar al contenido principal

MICROBIOTA INTESTINAL Y DAÑO HEPATICO POR FARMACOS (DILI). TRANSFERENCIA DE PERFILES ESPECIFICOS Y MODULACION DE MICROBIOTA EN MODELOS EXPERIMENTALES DE DILI POR CLAVULANATO

PID2020-120363RB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2020
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario UNIVERSIDAD DE LEÓN

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

BULERIA. Repositorio Institucional de la Universidad de León
Publicación Artículo científico (JournalArticle)

The Synbiotic Combination of Akkermansia muciniphila and Quercetin Ameliorates Early Obesity and NAFLD through Gut Microbiota Reshaping and Bile Acid Metabolism Modulation

  • Juárez Fernández, María
  • Porras Sanabria, David
  • Petrov, Petar
  • Román Sagüillo, Sara
  • García Mediavilla, María Victoria
  • Soluyanova, Polina
  • Martínez Flórez, Susana
  • González Gallego, Javier
  • Nistal González, Maria Esther
  • Jover Atienza, Ramiro
  • Sánchez Campos, Sonia
[EN] Gut microbiota plays a key role in obesity and non-alcoholic fatty liver disease (NAFLD), so synbiotics could be a therapeutic alternative. We aim to evaluate a nutritional intervention together with the administration of the bacteria Akkermansia muciniphila and the antioxidant quercetin in an in vivo model of early obesity and NAFLD. 21-day-old rats were fed with control or high-fat diet for six weeks. Then, all animals received control diet supplemented with/without quercetin and/or A. muciniphila for three weeks. Gut microbiota, NAFLD-related parameters, circulating bile acids (BAs) and liver gene expression were analyzed. The colonization with A. muciniphila was associated with less body fat, while synbiotic treatment caused a steatosis remission, linked to hepatic lipogenesis modulation. The synbiotic promoted higher abundance of Cyanobacteria and Oscillospira, and lower levels of Actinobacteria, Lactococcus, Lactobacillus and Roseburia. Moreover, it favored elevated unconjugated hydrophilic BAs plasma levels and enhanced hepatic expression of BA synthesis and transport genes. A. muciniphila correlated with circulating BAs and liver lipid and BA metabolism genes, suggesting a role of this bacterium in BA signaling. Beneficial effects of A. muciniphila and quercetin combination are driven by gut microbiota modulation, the shift in BAs and the gut-liver bile flow enhancement., SI, This work was supported by grants from Ministerio de Economía y Competitividad/FEDER (BFU2017-87960-R; PID2020-120363RB-I0), Junta de Castilla y León (FEDER) (GRS2126/A/2020; LE063U16; LE017P20), and Instituto de Salud Carlos III (PI17/01089, PI20/00690, cofunded by European Regional Development Fund “A way to achieve Europe”). MJF was supported by a fellowship from Ministerio de Ciencia, Innovación y Universidades (FPU18/06257); DP and SRS by a fellow-ship from Junta de Castilla y León cofunded by the European Social Fund; PP by Sara Borrell Postdoctoral Contract CD18/00158 from the Instituto de Salud Carlos III, cofunded by the European Social Fundation. CIBERehd is funded by the Instituto de Salud Carlos III, Spain.
BULERIA. Repositorio Institucional de la Universidad de León
Publicación Artículo científico (JournalArticle)

Effects of Melatonin and Akkermansia muciniphila on the Gut-Liver Axis in a MASLD-Associated Liver Fibrosis Model: An Integrative Multi-Omic Approach

  • González Robles, Alba María
  • San Miguel de Vega, Beatriz
  • Román Sagüillo, Sara Selva de
  • Juárez Fernández, María
  • Mauriz Gutiérrez, José Luis
  • Martínez Flórez, Susana
  • Nistal González, Maria Esther
  • García Mediavilla, María Victoria
  • Sánchez Campos, Sonia
[EN] Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common cause of chronic liver disease worldwide. Fibrosis is the main prognostic factor and the last reversible stage before cirrhosis, yet therapeutic options remain limited. Given the strong contribution of gut dysbiosis to MASLD progression, strategies targeting the gut microbiota are of growing interest. This study aims to evaluate the effect of melatonin, a well-known antioxidant, anti-inflammatory and antifibrotic compound, and Akkermansia muciniphila, a next-generation probiotic, on an MASLD-associated liver fibrosis model. Eight-week-old C57BL/6J mice were fed a control or Western diet supplemented with fructose and intraperitoneal CCl4 to induce liver fibrosis. After eight weeks, the animals received either no intervention, melatonin, A. muciniphila, or both for four weeks. Serum biochemistry, liver histology and gut and liver gene expression were evaluated and multi-omic analyses were performed, including gut microbiota profiling and faecal metabolomics. Statistical analyses assessed intergroup differences and correlations across datasets. Both interventions partially restored gut microbiota composition and functionality and modulated hepatic and intestinal gene expression. Melatonin and A. muciniphila exerted protective effects against MASLD-associated fibrosis, which supports their potential as adjunctive therapeutic strategies to mitigate liver injury through modulation of the gut–liver axis, SI, This work was supported by grants from the Ministerio de Ciencia e Innovación (PID2020-120363RB-I00), Junta de Castilla y León and the European Regional Development Fund (GRS2126/A/2020 and LE017-P20) and CIBERehd, is funded by the Instituto de Salud Carlos III (ISCIII). A.G.-R. was supported by a fellowship from Ministerio de Educación (FPU22/02734). M.J.-F. was supported by a fellowship from the Ministerio de Educación (FPU18/06257). S.R.-S was supported by a Fellowship to Finance the Predoctoral Recruitment of Research Personnel by the Junta of Castilla y Leon